Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case

@article{Jarius2016ScreeningFM,
  title={Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case},
  author={Sven Jarius and Imke Metz and Fatima Barbara K{\"o}nig and Klemens Ruprecht and Markus Reindl and Friedemann Paul and Wolfgang Br{\"u}ck and Brigitte Wildemann},
  journal={Multiple Sclerosis Journal},
  year={2016},
  volume={22},
  pages={1541 - 1549}
}
Background: Histopathological studies have revealed four different immunopathological patterns of lesion pathology in early multiple sclerosis (MS). Pattern II MS is characterised by immunoglobulin and complement deposition in addition to T-cell and macrophage infiltration and is more likely to respond to plasma exchange therapy, suggesting a contribution of autoantibodies. Objective: To assess the frequency of anti-myelin oligodendrocyte glycoprotein (MOG), anti-M1-aquaporin-4 (AQP4), anti-M23… Expand
Diagnosis of multiple sclerosis in times of MOG and AQP4 autoantibody testing – A monocentric study
TLDR
General testing of MOG and AQP4 autoantibodies in MS patients seems not necessary, but should be limited to selected cases only. Expand
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin
TLDR
This is the largest cohort studied for IgG to human full-length MOG by means of an up-to-date CBA and finds MOG-IgG is present in a substantial subset of patients with ON and/or myelitis, but not in classical MS. Expand
CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
TLDR
The CSF cytokine profile in the acute phase of MOG-IgG+ disease is characterised by coordinated upregulation of T helper 17 (Th17) and other cytokines including some Th1-related and regulatory T cells-related ones in adults and children, which is similar to AQP4-IGG+ NMOSD but clearly different from MS. Expand
Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis
TLDR
Antibodies to MOG can be found in a distinct subgroup of adult patients with clinically definite multiple sclerosis with a specific clinical phenotype and may indicate disease heterogeneity. Expand
Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients
TLDR
MOG-IgG-positive EM is characterized by CSF features that are distinct from those in multiple sclerosis, important for the differential diagnosis of MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease. Expand
Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients
TLDR
MOG-IgG-associated EM in children is characterized by CSF features that are distinct from those in MS and these findings are important for the differential diagnosis of pediatric MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease. Expand
Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration
TLDR
OCT features predominate in temporal pRNFL quadrants (resembling the MS retinal pattern), might be more severe than AQP4-abs-positive NMOSD, indicate subclinical pathology, and may be associated with MME. Expand
Deciphering anti-MOG IgG antibodies: Clinical and radiological spectrum, and comparison of antibody detection assays
TLDR
The findings support the wide spectrum of anti-MOG associated demyelinating disorders and the superiority of the MOG-IgG1 CBA over other Mog-CBAs. Expand
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients
TLDR
Retinal neuro-axonal damage and visual impairment after ON in MOG-IgG-positive patients are as severe as in AQP4-IGG- positive NMOSD patients. Expand
Myelin oligodendrocyte glycoprotein antibodies in neurological disease
TLDR
Antibodies against myelin oligodendrocyte glycoprotein (MOG-Abs) that are detectable with cell-based assays are associated with non-MS acquired demyelinating syndromes of the CNS, including the value of detection assays and evidence for antibody pathogenicity and its mechanism. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC
TLDR
A detailed review of the clinical and paraclinical features, oncological, therapeutic and prognostic implications, pathogenetic relevance, and differential laboratory diagnosis of the 12 most common PC autoantibodies (often referred to as ‘Medusa head antibodies’ due their characteristic somatodendritic binding pattern) is provided. Expand
Humoral pattern II multiple sclerosis pathology not associated with neuromyelitis Optica IgG.
TLDR
The NMO-IgG status of a cohort of patients with biopsy-proven early active lesions consistent with MS is reported, indicating a greater likelihood than other forms of MS to respond favorably to plasma exchange therapy. Expand
‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII
TLDR
A detailed review of the clinical and paraclinical features, oncological, therapeutic and prognostic implications, pathogenetic relevance, and differential laboratory diagnosis of the 12 most common PC autoantibodies (often referred to as ‘Medusa-head antibodies’ due to their characteristic somatodendritic binding pattern when tested by immunohistochemistry). Expand
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders
TLDR
It is shown for the first time that a subset of AQP4-IgG seronegative patients with NMO and HR-NMO exhibit a MOG-IGG mediated immune response, whereas MOG is not a target antigen in cases with an AQP 4-directed humoral immune response. Expand
‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook
TLDR
A detailed review of the clinical and paraclinical features, oncological, therapeutic and prognostic implications, pathogenetic relevance, and differential laboratory diagnosis of the 12 most common PC autoantibodies (often referred to as ‘Medusa head antibodies’ due to their characteristic somatodendritic binding pattern) is provided. Expand
Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?
While neuromyelitis optica (NMO) immunoglobulin (Ig) G is considered the hallmark serologic marker of NMO, its association is not absolute, as NMO IgG is not detected in approximately one-fourth ofExpand
The spectrum of MOG autoantibody-associated demyelinating diseases
TLDR
Cell-based immunoassays using MOG expressed in mammalian cells have demonstrated the presence of high-titre MOG antibodies in paediatric patients with acute disseminated encephalomyelitis, MS, aquaporin-4-seronegative neuromyELitis optica, or isolated optic neuritis or transverse myelitis; these studies indicate that Mog antibodies could be associated with a broad spectrum of acquired human CNS demyelinating diseases. Expand
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain
TLDR
Differences in the results mirror the better outcomes for MOG-IgG compared with AQP4-IGG patients and raise the possibility that Mog-IhG contributes to pathology in some neuromyelitis optica patients. Expand
Histopathology and clinical course of MOG-antibody-associated encephalomyelitis
TLDR
This case contributes a new, so far missing link in the emerging spectrum of MOG‐antibody‐associated encephalomyelitis and antibodies against myelin oligodendrocyte glycoprotein (MOG). Expand
NMO-IgG in the diagnosis of neuromyelitis optica
TLDR
It is shown that a newly detected serum autoantibody (called NMO-IgG) has been reported to distinguish between neuromyelitis optica (NMO) and multiple sclerosis (MS) and this proposal has important clinical implications and therefore demands independent confirmation. Expand
...
1
2
3
4
...